Mercedes Fernandez

 

Contact: mercefernandez@ub.edu   /   mercedes.fernandez@idibaps.org

Academic Role: Senior Group Leader

Biography: Mercedes Fernandez (Barcelona, 1967) is the Head of the Angiogenesis in Liver Disease Research Group at the IDIBAPS Biomedical Research Institute (Barcelona, Spain). She earned her Bachelor’s of Science degree in Biology from the University of Barcelona in 1990, and her PhD degree in Biology from the University of Barcelona in 1994. She conducted predoctoral research at the Liver Unit of the Hospital Clinic (Barcelona), the Wellcome Research Laboratories in Beckenham (United Kingdom) and the Department of Immunology of the Duke University in Durham (North Carolina, USA). From 1994 to 2002, she worked at USA as a postdoctoral researcher, first at the Department of Molecular and Cellular Physiology of the Louisiana State University Health Science Center (Shreveport, LA), and then at the Department of Medicine of the University of Massachusetts Medical School (Worcester, MA). From there, she moved back to Barcelona where she established her own research group first as a Ramon y Cajal Researcher and then as a Senior Group Leader at the IDIBAPS Biomedical Research Institute and the Biomedical Research Networking Center on Hepatic and Digestive Disease (CIBEREHD).

LinkedIn

ResearchGate

Publications

Pericytes in the gut

Ramirez M, Pell N, Mejias M, Fernandez M

Co-first authors: Marta Ramirez and Nuria Pell

Corresponding author: Mercedes Fernandez

Advances in Experimental Medicine and Biology, “Biology of Pericytes: Development, Homeostasis and Disease”. Springer (ISSN:0065-2598)(in press)

Placental growth factor: New treatment target bringing hope in hepatopulmonary syndrome

Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology (2018) doi:10.1002/hep.29795  PubMed    

Invited Editorial

Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress

Maillo C, Martin J, Sebastian D, Hernandez-Alvarez M, Garcia-Rocha M, Reina O, Zorzano A, Fernandez M, Mendez R

Co-corresponding authors: Raul Mendez and Mercedes Fernandez

Nature Cell Biology (2017) 19:94-105 PubMed

Comment on this paper: Moore PC & Oakes SA. CPEB4 links the clock and the UPR to protect the liver. Nature Cell Biology (2017);19:79-81. Comment

This paper received the Award to the Best Scientific Publication (Year 2018) from the Spanish Association Against Cancer (AECC) 

Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension

Gallego J, Garcia-Pras E, Mejias M, Pell N, Schaeper U, Fernandez M

Co-first authors: Javier Gallego and Ester Garcia-Pras

Corresponding author: Mercedes Fernandez

Scientific Reports (2017) 7:14791-14806  PubMed    Springer Nature SharedIt

Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension

Garcia-Pras E, Gallego J, Coch L, Mejias M, Fernandez-Miranda G, Pardal R, Bosch J, Mendez R, Fernandez M

Corresponding author: Mercedes Fernandez

Gut (2017) 66:1306-1320

Gastroesophageal varices

Fernandez M, Abraldes JG

Corresponding author: Mercedes Fernandez

In: Liver Pathophysiology: Therapies and Antioxidants (2017) Ed. Muriel P, Academic Press, Elsevier (ISBN: 978-0-12-804274-8)

Invited Review

Sequential functions of CPEB1 and CPEB4 regulate pathologic expression of VEGF and angiogenesis in chronic liver disease

Calderone V, Gallego J, Fernandez-Miranda G, Garcia-Pras E, Maillo C, Berzigotti A, Mejias M, Bava FA, Angulo-Urarte A, Graupera M, Navarro P, Bosch J, Fernandez M, Mendez R

Co-first authors: Javier Gallego and Vittorio Calderone

Co-corresponding authors: Raul Mendez and Mercedes Fernandez

Gastroenterology (2016) 150: 982-997

Pathogenesis of portal hypertension: Extrahepatic mechanisms

Fernandez M, Mejias M, Garcia-Pras E, Gallego J, Pell N, Ramirez M, Naranjo-Suarez S, Barrachina-Catala A

Corresponding author: Mercedes Fernandez

Current Hepatology Reports (2016) 15:199-207

Invited Review

Molecular pathophysiology of portal hypertension

Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology (2015) 61:1406-1415

Invited Review

Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats

Mejias M, Coch L, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Gut (2015) 64:657-666

Editorial devoted to this article: Vespasiani-Gentilucci U, Rombouts K. Boosting pigment epithelial-derived factor: a promising approach for the treatment of early portal hypertension. Gut (2015) 64:523-524

Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats

Coch L, Mejias M, Berzigotti A, Garcia-Pras E, Gallego J, Bosch J, Mendez R, Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology (2014) 60:633-647

Editorial devoted to this article: Chatterjee S. Reversal of vasohibin-driven negative feedback loop of vascular endothelial growth factor/angiogenesis axis promises a novel antifibrotic therapeutic strategy for liver diseases. Hepatology (2014) 60:458-460

Hepatology Highlights devoted to this article: Dufour JF. After vasopressin comes vasohibin. Hepatology (2014) 60:447 

Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats

D’Amico M, Mejias M, Garcia-Pras E, Abraldes JG, Garcia-Pagan JC, Fernandez M, Bosch J

American Journal of Physiology (2012) 302:G1191-G1198

Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension

Mejias M, Garcia-Pras E, Gallego J, Mendez R, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Hepatology (2010) 52:529-539

Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension

Bosch J, Abraldes JG, Fernandez M, Garcia-Pagan JC

Journal of Hepatology (2010) 53:558-567

Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats

Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Hepatology (2009) 49:1245-1256

Editorial devoted to this article: Shah VH, Bruix J. Antiangiogenic therapy: not just for cancer anymore? Hepatology 49:1066-1068 (2009)

Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension

Tiani C, Garcia-Pras E, Mejias M, de Gottardi A, Berzigotti A, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Hepatology (2009) 50:296-305

Angiogenesis in liver disease

Fernandez M, Semela D, Bruix J, Colle I, Pinzani M, Bosch J

Journal of Hepatology (2009) 50:604-620

As of September 2018, this “Highly Cited Paper” received enough citations (285) to place it in the top 1% of its academic field based on a highly cited threshold for the field and publications year. Data from Essential Science Indicators.

Impacto de los inhibidores de la angiogénesis en el tratamiento de la hipertensión portal

Fernandez M

Corresponding author: Mercedes Fernandez

Gastroenterología y Hepatología Continuada (2009) 8:312-317

Invited Review

The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats

Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Cellular and Molecular Medicine (2008) 12:1690-1699

Role of angiogenesis in portal hypertension

Fernandez M, Mejias M, Garcia-Pras E, Bosch J

Corresponding author: Mercedes Fernandez

In: Liver Cirrhosis: From Pathophysiology to Disease Management (2008) Edited by: Bosch J, Burroughs AK, Lammert F, Sauerbruch T, Lebrec D. Springuer, Dordrecht, The Netherlands. Volume 162, pages 112-129

Invited Review

Increased oxidative stress in cirrhotic livers. A potential mechanism contributing to reduce nitric oxide bioavailability

Gracia-Sancho J, Laviña B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Fernandez M, Bosch J, Garcia-Pagan JC

Hepatology (2008) 47:1248-1256

Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats

Matei V, Rodriguez-Vilarrupla A, Deulofeu R, Garcia-Caldero H, Fernandez M, Bosch J, Garcia-Pagan JC

Journal of Hepatology (2008) 49:192-197

Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats

Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J

Corresponding author: Mercedes Fernandez

Hepatology (2007) 46: 1208-1217

This paper received the Award to the Best Publication in Hepatology Research (Year 2007), from the Spanish Association for the Study of the Liver

NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats

Angermayr B, Fernandez M, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J

Corresponding author: Mercedes Fernandez

Gut (2007) 56:560-564

Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis

Gracia-Sancho J, Laviña B, Rodriguez-Vilarrupla A, Brandes RP, Fernandez M, Bosch J, Garcia-Pagan JC

Gastroenterology (2007) 133:959-966

Current concepts on the pathophysiology of portal hypertension

Rodriguez-Vilarrupla A, Fernandez M, Bosch J, Garcia-Pagan JC

Annals of Hepatology (2007) 6:28-36

Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats

Angermayr B, Mejias M, Gracia-Sancho J, Garcia-Pagan JC, Bosch J, Fernandez M

Corresponding author: Mercedes Fernandez

Journal of Hepatology (2006) 44:1033-1039

The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis

Matei V, Rodriguez-Vilarrupla A, Deulofeu R, Colomer D, Fernandez M, Bosch J, Garcia-Pagan JC

Hepatology (2006) 44:44-52

Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats

Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodes J, Bosch J

Corresponding author: Mercedes Fernandez

Journal of Hepatology (2005) 43:98-103

Editorial devoted to this article: Moreau R. “VEGF-induced angiogenesis drives collateral circulation in portal hypertension”. J Hepatol 2005;43:6-8.

Heme oxygenase in portal hypertension and liver disease

Lambrecht RW, Fernandez M, Shan Y, Bonkovsky HL

In: Ascites and Renal Dysfunction in Liver Disease (2005). Pathogenesis, Diagnosis and Treatment. Edited by: Gines P, Arroyo V, Rodes J, Schrier RW. Blackwell Publishing Ltd, Oxford, United Kingdom. Pages 125-136 (2005)

Invited Review

Chronische blockade von häm-oxigenase im portal hypertensiven rattenmodell: Effekte auf angiogenese, oxidativen stress und inflammation

Angermayr B, Mejias M, Gracia-Sancho J, March S, Peck-Radosavljevic M, Garcia-Pagan JC, Bosch J, Fernandez M

Zeitschrift für Gastroenterologie (2005) doi: 10.1055/s-2005-869607

Oxidativer stress trägt zur hyperdynamen zirkulation im portal-hypertensiven rattenmodell

Angermayr B, Mejias M, Peck-Radosavljevic M, Garcia-Pagan JC, Rodes J, Bosch J, Fernandez M

Zeitschrift für Gastroenterologie (2005) 43;05

Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis

Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernandez M, Garcia-Pagan JC, Rodes J, Bosch J

Gastroenterology (2004) 126:749-755

Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice

Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J

Corresponding author: Mercedes Fernandez

Gastroenterology (2004) 126:886-894

Effects of V-1A vasopressin receptor agonist F-180 on portal hypertension-related bleeding in portal hypertensive rats

Morales J, Moitinho E, Abraldes JG, Fernandez M, Bosch J

Hepatology (2003) 38:1378-1383

Vascular endothelial growth factor increases heme oxygenase-1 expression in the chicken embryo chorioallantoic membrane

Fernandez M, Bonkovsky HL

Corresponding author: Mercedes Fernandez

British Journal of Pharmacology (2003) 139:634-640

Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: Role in modulating mesenteric vascular reactivity

Fernandez M, Lambrecht RW, Bonkovsky HL

Corresponding author: Mercedes Fernandez

Journal of Hepatology (2001) 34:812-817

Editorial devoted to this article: Moreau R. Heme oxygenase: protective enzyme or portal hypertensive molecule? Journal of Hepatology (2001) 34:936-939

Duration of the hemodynamic effects of N(G)-nitro-L-arginine methyl ester in vivo

Conner EM, Aiko S, Fernandez M, Battarbee HD, Gray L, Grisham MB

Nitric Oxide. Biology and Chemistry (2000) 4:85-93

Increased heme oxygenase-1 gene expression in liver cells and splanchnic organs from portal hypertensive rats

Fernandez M, Bonkovsky HL

Corresponding author: Mercedes Fernandez

Hepatology (1999) 29:1672-1679

Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition

Bandi JC, Fernandez M, Bernadich C, De Lacy AM, Garcia-Pagan JC, Bosch J, Rodes J

Journal of Hepatology (1999) 31:719-724

Constitutive nitric oxide synthase isoforms account for gastric mucosal nitric oxide overproduction in uremic rats

Mendez A, Fernandez M, Barrios Y, Lopez-Coviella I, Gonzalez-Mora JL, Rivero M, Salido E, Bosch J, Quintero E

American Journal of Physiology (1997) 272:G894-G901

Mechanical pumping of portal blood to the liver: hemodynamic effects of a new experimental treatment for portal hypertension

Bernadich C, Fernandez M, Bandi JC, Bosch J, Rodes J

Journal of Hepatology (1996) 25:98-105

Acute and chronic cyclooxygenase blockade in portal hypertensive rats: Influence on nitric oxide biosynthesis

Fernandez M, Garcia-Pagan JC, Casadevall M, Mourelle MI, Pique JM, Bosch J, Rodes J

Gastroenterology (1996) 110:1529-1535

Drug therapy in primary and secondary prevention of variceal hemorrhage in portal hypertension

Bosch J, D’Amico G, Feu F, Luca A, Garcia-Pagan JC, Fernandez M, Escorsell A, Pagliaro L

In: Liver Diseases: Prevention, Inhibition of Progression, and Rehabilitation (1995). Edited by: Nilius R, Paquet KJ. Karger, Basel, Switzerland. Pages 137-147

Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double-blind hemodynamic investigation

Cirera I, Feu F, Luca A, Garcia-Pagan JC, Fernandez M, Escorsell A, Bosch J, Rodes J

Hepatology (1995) 22:106-111

Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis

Luca A, Garcia-Pagan JC, Feu F, Lopez-Talavera JC, Fernandez M, Bru C, Bosch J, Rodes J

Hepatology (1995) 21:83-88

Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats

Fernandez M, Garcia-Pagan JC, Casadevall M, Bernadich C, Piera C, Whittle BJR, Pique JM, Bosch J, Rodes J

Gastroenterology (1995) 108:1487-1495

Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis

Luca A, Garcia-Pagan JC, Bosch J, Feu F, Jimenez W, Gines A, Fernandez M, Escorsell A, Arroyo V, Rodes J

Hepatology (1995) 22:753-758

Alterations in soluble and leukocyte surface L-selectin (CD62L) in hemodialysis patients

Rabb H, Agosti SJ, Bittle PA, Fernandez M, Ramirez G, Tedder TF.

Journal of the American Society of Nephrology (1995) 6:1-6

Impaired function of pancreatic islets from rats with portal hypertension due to cirrhosis and partial portal vein ligation

Gomis R, Fernandez J, Pizcueta P, Fernandez M, Casamitjana R, Bosch J, Rodes J

Hepatology (1994) 19:1257-1261

Nicardipine increases hepatic blood flow and the hepatic clearance of ICG in patients with cirrhosis

Garcia-Pagan JC, Feu F, Luca A, Fernandez M, Pizcueta P, Bosch J, Rodes J

Hepatology (1994) 20:792-796

Gastric microcirculatory changes of portal hypertensive rats can be attenuated by chronic estrogen-progestagen treatment

Panes J, Casadevall M, Fernandez M, Pique JM, Bosch J, Casamitjana R, Cirera I, Bombi JA, Teres J, Rodes J

Hepatology (1994) 20:1261-1270

Effects of continued nitric oxide inhibition on portal hypertensive syndrome after portal vein stenosis in rat

Garcia-Pagan JC, Fernandez M, Bernadich C, Pizcueta P, Pique JM, Bosch J, Rodes J

American Journal of Physiology (1994) 267:G984-G990

Neonatal capsaicin treatment does not prevent the splanchnic vasodilation in portal hypertensive rats

Fernandez M, Casadevall M, Schuligoi R, Pizcueta P, Panes J, Barrachina MD, Donnerer J, Pique JM, Esplugues JV, Bosch J, Rodes J, Holzer P

Hepatology (1994) 20:1609-1614

Pathophysiology of portal hypertension

Bosch J, Fernandez M, Bernadich C, Pizcueta P

In: Proceedings 4th World Congress (1994). International Gastro-Surgical Club, Symposium: Portal Hypertension. Jarpyo Editores, Madrid. Pag. 493-495

Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamic in rats with long-term bile duct ligation

Fernandez M, Pizcueta P, Garcia-Pagan JC, Feu F, Cirera I, Bosch J, Rodes J

Hepatology (1993) 18:389-393

New approaches in the pharmacologic treatment of portal hypertension

Bosch J, Garcia-Pagan JC, Feu F, Luca A, Fernandez M, Pizcueta P, Rodes J

Journal of Hepatology (1993) 17:S41-S45

Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition

Pizcueta P, Pique JM, Fernandez M, Bosch J, Rodes J, Whittle BJR, Moncada S

Gastroenterology (1992) 103:1909-1915

Pathophysiology of portal hypertension

Bosch J, Pizcueta P, Feu F, Fernandez M, Garcia-Pagan JC

Gastroenterology Clinics of North America (1992) 21:1-14

Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension

Bosch J, Pizcueta MP, Fernandez M, Feu F, Cirera I, Luca A, Garcia-Pagan JC

Bailliere’s Clinical Gastroenterology (1992) 6:425-436

Role of nitric oxide in the hyperdynamic splanchnic circulation of portal hypertensive rats

Pique JM, Pizcueta MP, Bosch J, Fernandez M, Whittle BJR, Moncada S

In: The Biology of  Nitric Oxide. I Physiological and Clinical Aspects (1992) Edited by: Moncada S, Marletta MA, Hibbs JB, Higgs EA. Portland Press, London. Pages 60-64

Effects of ritanserin, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats

Nevens F, Pizcueta P, Fernandez M, Bosch J, Rodes J

Hepatology (1991) 14:1174-1178

Glucagon hinders the effects of somatostatin on portal hypertension

Pizcueta MP, Garcia-Pagan JC, Fernandez M, Casamitjana R, Bosch J, Rodes J

Gastroenterology (1991) 101:1710-1715

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.plugin cookies

ACEPTAR
Aviso de cookies